case_images: PMC10293966_01
case_images: PMC10293966_02
case_images: PMC10293966_03
case_images: Blood cell transition of the patient. [1], thirteen days before atezolizumab initiation; [2], baseline; [3], day 9 of the first atezolizumab administration; [4], day 13 of the first atezolizumab administration; [5], day 15 of the first atezolizumab administration; [6], day 1 of the second atezolizumab administration; [7], day 22 of the second atezolizumab administration (neutropenia detection); [8], day 23 of the second atezolizumab administration (hospitalization); [9], day 28 of the second atezolizumab administration (the day before the third cycle); [10], day 7 of the third atezolizumab administration; [11], day 1 of the fourth atezolizumab administration; [12], day 1 of the sixth atezolizumab administration; [13], day 1 of the eighth atezolizumab administration; [14], day 1 of the tenth atezolizumab administration; [15], day 1 of the twelfth atezolizumab administration.
case_images: cro530338_f01.jpg
case_images: PMC10293966_03_cro530338_f01.jpg
case_images: F1
case_images: Figure 1 shows the fluctuations in neutrophil count and monocyte fractionation during treatment.